The knockdown of RRAD diminished the survival of bortezomib-resistant cancer cells by inducing mitochondrial apoptosis via proapoptotic Noxa/Bcl-2 modulation, which might be caused by caspase activation. The gene discussed is RRAD; the disease is cancer.